Inhaled amphotericin

Phase 2Small molecule

PPost Graduate Institute of Medical Education and Research, Chandigarh

Inhaled amphotericin is one of 13 small molecule programs targeting Mucormycosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MucormycosisActive, not recruiting

Allergic Bronchopulmonary AspergillosisActive, not recruiting

MucormycosisPhase 2

Active, not recruiting

Allergic Bronchopulmonary AspergillosisPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Mucormycosis

#DrugCompanyPhaseTrials

Abelcet

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 2

Noxafil

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Exjade

1 4

Liposomal Lurtotecan

Gilead

Phase 2

3 5

Inhaled amphotericin

PPost Graduate Institute of Medical Education and Research, Chandigarh

Phase 2

1 6

Isavuconazole

Astellas

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mucormycosis1 trial

Combined Inhalational With Intravenous Amphotericin B Versus Intravenous Amphotericin B Alone for Pulmonary Mucormycosis

Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2·NCT04502381·30 enrolled

Allergic Bronchopulmonary Aspergillosis1 trial

A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis

Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2/3·NCT01857479·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Inhaled amphotericin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inhaled amphotericin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inhaled amphotericin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Post Graduate Institute of Medical Education and Research, Chandigarh company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPost Graduate Institute of Medical Education and Research, Chandigarh

Inhaled amphotericin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mucormycosis1 trial

Allergic Bronchopulmonary Aspergillosis1 trial

References

Drug Info

Quick Facts

Related News